BACKGROUND: DNA methylation is an important mechanism for gene silencing and has already been described for several genes in breast cancer. A previous immunohistochemistry study demonstrated a decrease of K(v)1.3 potassium channel expression in breast adenocarcinoma compared to normal breast tissue. METHODS: Methyl-specific PCR (MSP), immunohistochemistry and RNA extraction were performed on breast adenocarcinoma. MSP and DNA extraction were also performed on one breast carcinoma cell line and on primary culture normal cells. RESULTS: DNA methylation of K(v)1.3 gene promoter was observed in 42.3% of samples (22/52). The methylated status was associated with poorly differentiated tumors (p=0.04) and younger patients (p=0.048). Decreased K(v)1.3 expression was observed in grade III tumors, at both the mRNA and protein levels, while methylation increased in grade III tumors. Finally, K(v)1.3 gene promoter was methylated in the MCF-7 breast carcinoma cell line while promoter methylation was absent in primary culture of normal breast cells (HMEpC). CONCLUSION: We report, for the first time, the methylation of the K(v)1.3 gene promoter in breast adenocarcinoma. Our data suggest that DNA methylation is responsible for a decrease of K(v)1.3 gene expression in breast adenocarcinoma and is associated with poorly differentiated tumors and younger patients. 2009 S. Karger AG, Basel.
BACKGROUND: DNA methylation is an important mechanism for gene silencing and has already been described for several genes in breast cancer. A previous immunohistochemistry study demonstrated a decrease of K(v)1.3 potassium channel expression in breast adenocarcinoma compared to normal breast tissue. METHODS: Methyl-specific PCR (MSP), immunohistochemistry and RNA extraction were performed on breast adenocarcinoma. MSP and DNA extraction were also performed on one breast carcinoma cell line and on primary culture normal cells. RESULTS: DNA methylation of K(v)1.3 gene promoter was observed in 42.3% of samples (22/52). The methylated status was associated with poorly differentiated tumors (p=0.04) and younger patients (p=0.048). Decreased K(v)1.3 expression was observed in grade III tumors, at both the mRNA and protein levels, while methylation increased in grade III tumors. Finally, K(v)1.3 gene promoter was methylated in the MCF-7 breast carcinoma cell line while promoter methylation was absent in primary culture of normal breast cells (HMEpC). CONCLUSION: We report, for the first time, the methylation of the K(v)1.3 gene promoter in breast adenocarcinoma. Our data suggest that DNA methylation is responsible for a decrease of K(v)1.3 gene expression in breast adenocarcinoma and is associated with poorly differentiated tumors and younger patients. 2009 S. Karger AG, Basel.
Authors: Špela Gubič; Louise A Hendrickx; Žan Toplak; Maša Sterle; Steve Peigneur; Tihomir Tomašič; Luis A Pardo; Jan Tytgat; Anamarija Zega; Lucija P Mašič Journal: Med Res Rev Date: 2021-05-01 Impact factor: 12.944
Authors: Brandon M Schickling; Nukhet Aykin-Burns; Kimberly K Leslie; Douglas R Spitz; Victoria P Korovkina Journal: Cancer Cell Int Date: 2011-08-02 Impact factor: 5.722
Authors: Jung H Kim; Alla Karnovsky; Vasudeva Mahavisno; Terry Weymouth; Manjusha Pande; Dana C Dolinoy; Laura S Rozek; Maureen A Sartor Journal: BMC Genomics Date: 2012-10-04 Impact factor: 3.969
Authors: Núria Comes; Joanna Bielanska; Albert Vallejo-Gracia; Antonio Serrano-Albarrás; Laura Marruecos; Diana Gómez; Concepció Soler; Enric Condom; Santiago Ramón Y Cajal; Javier Hernández-Losa; Joan C Ferreres; Antonio Felipe Journal: Front Physiol Date: 2013-10-10 Impact factor: 4.566